Corline Biomedical
17.55 SEK
-1.13 %
Less than 1K followers
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-1.13 %
-9.77 %
+17.00 %
+80.93 %
+99.89 %
+137.80 %
+84.35 %
+25.33 %
+77.42 %
Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.
Read moreMarket cap
449.52M SEK
Turnover
16.16K SEK
Revenue
9.78M
EBIT %
-236.91 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
17/2
2026
Annual report '25
8/5
2026
Interim report Q1'26
26/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming
Corline Biomedical AB offentliggör delårsrapport för perioden januari till september 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools